---
title: Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease
nct_id: NCT06435858
overall_status: RECRUITING
phase: PHASE2
sponsor: Cantonal Hospital Graubuenden
study_type: INTERVENTIONAL
primary_condition: Autosomal Dominant Polycystic Kidney Disease
countries: Switzerland
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06435858.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06435858"
ct_last_update_post_date: 2025-09-12
last_seen_at: "2026-05-12T06:44:09.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease

**NCT ID:** [NCT06435858](https://clinicaltrials.gov/study/NCT06435858)

## Key Facts

- **Status:** RECRUITING
- **Phase:** PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 40
- **Lead Sponsor:** Cantonal Hospital Graubuenden
- **Collaborators:** University of Zurich
- **Conditions:** Autosomal Dominant Polycystic Kidney Disease
- **Start Date:** 2024-09-01
- **Completion Date:** 2025-10
- **CT.gov Last Update:** 2025-09-12

## Brief Summary

This study aims to better understand electrolyte handling in patients with autosomal dominant polycystic kidney disease treated with the SGLT2 inhibitor Empagliflozin.

Patients will be randomized into two groups and take Empagliflozin or a Placebo for 2 weeks with a wash-out period of 2 weeks. The primary outcome is tubular handling of the divalent ions calcium, phosphate and magnesium. Secondary outcomes include diuresis, safety and tolerability.

## Detailed Description

This investigator-initiated randomised, single-blind, placebo-controlled cross-over study aims to better understand tubular electrolyte handling of divalent ions in patients with autosomal dominant polycystic kidney disease treated with the SGLT2 inhibitor Empagliflozin.

After randomization, at week 0, participants collect 24-hour urine sample and a patient visit to assess vitals and blood tests takes place. After this visit, period 1 starts with a 2-week treatment of either Empagliflozin 10mg or Placebo.

At week 2, the second 24-hour-urine sample and 2. patient visit and blood test take place. After this visit, wash-out period for 2 weeks starts where no study drug will be administered At week 4, the period 2, the crossover-period starts for an additional 2 weeks. At week 6; a final and third 24-hour urine sample, clinical visit and blood test takes place.

At week 3 \& 7, a phone consultation will assess safety.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 75 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* \- Patients 18-75 years old with ADPKD, defined according to international diagnostic and classification criteria14, treated at Cantonal Hospital Graubünden (KSGR) and the University Hospital Zürich (USZ) independent of baseline treatment with the vasopressin receptor antagonist Tolvaptan
* Informed consent as documented by signature

Exclusion Criteria:

* \- renal replacement therapy or kidney allograft recipient
* chronic kidney disease CKD KDIGO Stage G4 (eGFR under 30ml/min/1.73m2)
* patients younger 18 years of age
* Diabetes mellitus type 1
* recurrent urinary tract infections (UTI) defined as more than 3 infections requiring antibiotic treatment or over 1 requiring hospitalization/year.
* Patients with uncontrolled hypertension (defined as ambulatory systolic BP over 180mmHg), liver cirrhosis (Child Pugh B and C)
* Patients not able or not willing to stop the following medications during the study period of participation in the trial:
* Thiazide diuretics
* Carbonic anhydrase inhibitors
* Sodium bicarbonate
* 1, 25 (OH) vitamin D (calcitriol)
* Bisphosphonate, denosumab, teriparatide
* Pregnant or lactating women
* Known allergy to study drug
* Inability to understand and follow the protocol
```

## Arms

- **Intervention** (EXPERIMENTAL) — Empagliflozin 10mg
- **Control** (PLACEBO_COMPARATOR) — Placebo

## Interventions

- **Empagliflozin** (DRUG) — Empagliflozin 10mg
- **Placebo** (DRUG) — Placebo capsule

## Primary Outcomes

- **Primary Outcome** _(time frame: After a two week intervention)_ — \- Calcium, phosphate, magnesium excretion

## Secondary Outcomes

- **Secondary Outcome** _(time frame: After a two week intervention)_

## Locations (2)

- University Hospital Zurich, Division of Nephrology, Zurich, Canton of Zurich, Switzerland — _RECRUITING_
- Cantonal Hospital Graubuenden, Chur, Kanton Graubünden, Switzerland — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.university hospital zurich, division of nephrology|zurich|canton of zurich|switzerland` — added _(2026-05-12)_
- `locations.cantonal hospital graubuenden|chur|kanton graubünden|switzerland` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06435858.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06435858*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*